Integrated Biopharma Files 8-K
Ticker: INBP · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1016504
| Field | Detail |
|---|---|
| Company | Integrated Biopharma Inc (INBP) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financial-reporting
TL;DR
IBP filed an 8-K on Dec 2 for shareholder votes and financials.
AI Summary
Integrated Biopharma, Inc. filed an 8-K on December 2, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not contain specific details on the votes or financial figures within the provided text.
Why It Matters
This filing indicates that Integrated Biopharma has submitted matters for shareholder vote and is providing financial statements, which are key events for investors to monitor company governance and financial health.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial reporting, not indicating any immediate operational or financial distress.
Key Players & Entities
- INTEGRATED BIOPHARMA, INC. (company) — Registrant
- December 2, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-31668 (identifier) — Commission File Number
- 22-2407475 (identifier) — I.R.S. Employer Identification No.
- INTEGRATED HEALTH TECHNOLOGIES INC (company) — Former Company Name
- CHEM INTERNATIONAL INC (company) — Former Company Name
FAQ
What specific matters were submitted to a vote of security holders by Integrated Biopharma, Inc. on or around December 2, 2024?
The provided text of the 8-K filing indicates that 'Submission of Matters to a Vote of Security Holders' is an item reported, but does not specify the exact matters.
What are the key financial statements included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in the provided excerpt.
When was Integrated Biopharma, Inc. previously known as Integrated Health Technologies Inc.?
The date of the name change from Integrated Health Technologies Inc. to Integrated Biopharma, Inc. was September 12, 2002.
What is the fiscal year end for Integrated Biopharma, Inc.?
The fiscal year end for Integrated Biopharma, Inc. is June 30.
Where is Integrated Biopharma, Inc. located based on the filing?
The business and mailing address for Integrated Biopharma, Inc. is listed as 225 Long Avenue, Building 15, Hillside, NJ 07205.
Filing Stats: 758 words · 3 min read · ~3 pages · Grade level 11.3 · Accepted 2024-12-02 14:54:28
Key Financial Figures
- $0.002 — f the Company's common stock, par value $0.002 per share, were entitled to vote as of
Filing Documents
- inbp20241202_8k.htm (8-K) — 46KB
- 0001437749-24-036441.txt ( ) — 165KB
- inbp-20241202.xsd (EX-101.SCH) — 3KB
- inbp-20241202_def.xml (EX-101.DEF) — 10KB
- inbp-20241202_lab.xml (EX-101.LAB) — 14KB
- inbp-20241202_pre.xml (EX-101.PRE) — 10KB
- inbp20241202_8k_htm.xml (XML) — 2KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders On December 2, 2024, Integrated BioPharma, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 30,099,610 shares of the Company's common stock, par value $0.002 per share, were entitled to vote as of the close of business on October 15, 2024, the record date for the Annual Meeting. The holders of 21,933,260 shares of common stock, representing a quorum, were present in person or represented by proxy at the Annual Meeting, at which the stockholders were asked to vote on two proposals. The proposals are described in detail in the Company's definitive proxy materials which were filed with the Securities and Exchange Commission and first made available to stockholders on or about October 28, 2024 (the "Definitive Proxy Statement"). At the Annual Meeting, Mr. Damon DeSantis and Mrs. Riva Sheppard were elected as Class I directors to serve until the 2027 Annual Meeting of Stockholders (subject to their respective earlier removal, death or resignation) and until their successors are elected and qualified. The Company's stockholders ratified the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2025. Proposal No. 1 – To elect two Class I directors for a three-year term to serve until the 2027 Annual Meeting of Stockholders The Company's stockholders voted for the election of two Class I directors, Mr. Damon DeSantis and Mrs. Riva Sheppard, to serve until the 2027 Annual Meeting of Stockholders (subject to their respective earlier removal, death or resignation) and until their successor is elected and qualified. The final voting results were as follows: Broker For Withheld Non-Votes Damon DeSantis 20,448,871 142,036 1,342,353 Riva Sheppard 20,301,671 289,236 1,342,353 Proposal No. 2 – To ratify the appointment of the Company ' s independent auditors for the fiscal year
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibit relating to Item 5.07 shall be deemed to be furnished, and not filed: 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1- EXHIBIT INDEX Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTEGRATED BIOPHARMA, INC. Date: December 2, 2024 By: /s/ Dina L Masi Dina L Masi Chief Financial Officer -3-